PBAC to consider semaglutide listing for weight loss

The drug is still not marketed in Australia despite being registered last September.

Novo Nordisk has applied for PBS funding for its subcutaneous weight loss drug Wegovy as a severe obesity treatment.

The product contains the GLP-1 receptor agonist semaglutide — the same active ingredient as Ozempic — and was approved by the TGA in September last year for adults with obesity, or overweight in the presence of at least one weight-related comorbidity.